Surgery and cancer after endometrial resection. Long-term follow-up on menstrual bleeding and hormone treatment by questionnaire and registry

Krogh, Rubab Agha; Lauszus, Finn Friis; Guttorm, Eigil; Rasmussen, Kirsten

doi:10.1007/s00404-009-0989-0

Cited by 20 publications

(22 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are in agreement with Krogh et al, 125 who found no significant increase in the incidence of endometrial cancer after ablation in a Danish population. We found no significant difference in the risk of ovarian cancer between women undergoing EA and those who had a hysterectomy.…”

Section: Interpretation Of Findingssupporting

confidence: 94%

Hysterectomy, endometrial ablation and Mirena® for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis

Bhattacharya

Middleton²,

Tsourapas³

et al. 2011

Health Technol Assess

100

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of project...

show abstract

Section: Interpretation Of Findingssupporting

confidence: 94%

Hysterectomy, endometrial ablation and Mirena® for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis

Bhattacharya

Middleton²,

Tsourapas³

et al. 2011

Health Technol Assess

100

View full text Add to dashboard Cite

show abstract

“…36 Failure of EA is associated with preoperative dysmenorrhea or tubal ligation. 36 Although EA does not appear to increase the risk of EC, 37,38 EC can occur after ablation. Endometrial cancer is associated with type II diabetes mellitus, obesity, hypertension, colon cancer, anovulatory syndromes such as polycystic ovarian syndrome, history of endometrial hyperplasia, and failure of progestin treatment of any cause of AUB.…”

Section: Aub Caused By Anatomic Abnormalitiesmentioning

confidence: 97%

“…Residual endometrium is present after EA, and a post-EA uterine cavity assessment with an office biopsy or sonohysterography is unsuccessful in one-quarter of women. 40 In addition, although EA does not appear to increase the risk of EC, 37,38 EA in the context of tamoxifen use has not been well studied. Definitive management via hysterectomy can be considered for women who have uncontrolled AUB associated with tamoxifen use and have completed their childbearing.…”

Section: Tamoxifen Use and Aubmentioning

confidence: 99%

Challenges in the Gynecologic Care of Premenopausal Women With Breast Cancer

Bakkum-Gamez

Laughlin

Jensen

et al. 2011

Mayo Clinic Proceedings

View full text Add to dashboard Cite

). © 2011 Mayo Foundation for Medical Education and ResearchB reast cancer is the leading cause of cancer death in women in the United States who are aged 20 to 59 years. 1 In 2010, an estimated 207,090 new cases of breast cancer were identified in the United States. 2 Although breast cancer risk increases with age, approximately 35% of breast cancers occur during the reproductive and perimenopausal years. 3 The 5-year relative survival rate for women of all ages with breast cancer diagnosed between 1999 and 2005 is 89%. 3 Of the premenopausal breast cancers diagnosed, approximately 58% are both estrogen receptor (ER) and progesterone receptor (PR) positive, 6% are ER positive only, 17% are PR positive only, and 20% are both ER and PR negative. 4 The management and treatment of breast cancer in premenopausal women can affect menstruation, reproduction, and gynecologic health. Breast cancer treatment can have a marked affect on fertility in women who have delayed childbearing and have fewer remaining reproductive years. Among premenopausal women with breast cancer, more than 50% wish to retain their fertility. 5 AUB = abnormal uterine bleeding; E2 = estradiol; EA = endometrial ablation; EC = endometrial cancer; ER = estrogen receptor; FDA = Food and Drug Administration; GnRH = gonadotropin-releasing hormone; IUD = intrauterine device; LNG = levonorgestrel; NSAID = nonsteroidal anti-inflammatory drug; PR = progesterone receptor; SHBG = sex hormone-binding globulin gynecologic issues and conditions are prevalent in reproductive-age women. In the general population, more than 30% of reproductive-age women fulfill criteria for the diagnosis of menorrhagia, 6 25% have symptomatic fibroids, 7 and nearly 67% have an underlying uterine disorder with potential to cause abnormal uterine bleeding (AUB). 8 Among premenopausal women with breast cancer, management of menstrual disorders, contraception, vasomotor symptoms, and fertility presents a challenge. Common and effective hormonal options are less well studied in this population because of significant concern about recurrence of breast cancer. Herein,we present the challenges and discuss management options for young women with breast cancer who present with various common gynecologic conditions.Articles for this review were identified by searching the PubMed database with no date limitations. PREMENoPAUSAL SEx STERoIDS AND THEIR PHARMACoLoGyPhysiologically, premenopausal women with regular cycles have cyclic variation in levels of estradiol (E2) (15-350 pg/ mL [to convert to pmol/L, multiply by 3.671]) and progesterone (0.2-27 ng/mL [to convert to nmol/L, multiply by 3.18]). These "free" (unbound) hormones are biologically active and can enter a target cell and activate its receptor.

show abstract

“…The alternative remains that ablation may destroy pre-malignant cells that are vulnerable to the ablation techniques, and instead reduce a woman's risk of endometrial cancer. These hypotheses have only been investigated in underpowered studies with inadequate or absent controls (31-33). …”

Section: Introductionmentioning

confidence: 99%

Endometrial Cancer After Endometrial Ablation vs Medical Management of Abnormal Uterine Bleeding

Dood

Gracia

Sammel

et al. 2014

Journal of Minimally Invasive Gynecology

View full text Add to dashboard Cite

Study Objective To investigate whether endometrial ablation carries an increased risk or delayed diagnosis of endometrial cancer compared to medical management for abnormal uterine bleeding. Design A multi-centered retrospective cohort study comparing rates of endometrial cancer in women who underwent treatment for abnormal uterine bleeding. Design Classification Canadian Task-Force Classification II-2 Setting This study was conducted using data from The Health Improvement Network (THIN), a representative population-based cohort of patients in 495 outpatient General Practitioner practices in the UK. Participants Women >25 years of age with an abnormal uterine bleeding diagnosis between June 1994 and September 2010. Interventions Endometrial ablation, medical management, or both. Measurements and Main Results A total of 234,721 women met study inclusion and exclusion criteria, 4,776 of whom underwent endometrial ablation and the remaining 229,945 underwent medical management. Cox models compared endometrial cancer rates between ablation and medical management groups using hazard ratios (HRs). To investigate a possible diagnostic delay, the median time from bleeding diagnosis to endometrial cancer diagnosis among women who developed endometrial cancer was compared using the Mann-Whitney U test. All statistical tests were two-tailed with α=.05. Over a median observation time of 4.07 years (IQR, 1.88-7.17), three and 601 women developed endometrial cancer in the ablation and medical management groups, respectively (ablation HR, 0.45; 95% CI, 0.15-1.40; p=.17). Median time to diagnosis was 237 and 299 days (ablation IQR, 155-1350; medical management IQR, 144-1,133.5; p=.99) in the ablation and medical management groups, respectively. Adjusted and sensitivity analyses did not change the results. Conclusions No difference was seen in endometrial cancer rates, nor was there a delay in diagnosis when comparing endometrial ablation versus medical management. Further studies are needed to investigate the impact of prior ablation exposure on histology or cancer stage at presentation of endometrial cancer.

show abstract

Surgery and cancer after endometrial resection. Long-term follow-up on menstrual bleeding and hormone treatment by questionnaire and registry

Abstract: Endometrial ablation is an effective form of treatment for menorrhagia with no increase in the incidence of endometrial cancer. Hormonal treatment does not seem to have any influence on the course of events.

Cited by 20 publications

References 13 publications

Hysterectomy, endometrial ablation and Mirena® for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis

Hysterectomy, endometrial ablation and Mirena® for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis

Challenges in the Gynecologic Care of Premenopausal Women With Breast Cancer

Endometrial Cancer After Endometrial Ablation vs Medical Management of Abnormal Uterine Bleeding

Contact Info

Product

Resources

About